KRAS G12V突变作为携带BRAF V600E突变的癌症用达非尼和曲美替尼治疗后获得性耐药性机制的一例报告

{"title":"KRAS G12V突变作为携带BRAF V600E突变的癌症用达非尼和曲美替尼治疗后获得性耐药性机制的一例报告","authors":"H. Oi, K. Yoh, S. Matsumoto, H. Izumi, Y. Shibata, T. Sakai, K. Nosaki, Y. Zenke, K. Goto","doi":"10.21037/pcm-21-55","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":74487,"journal":{"name":"Precision cancer medicine","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"KRAS G12V mutation as an acquired resistance mechanism after treatment with dabrafenib and trametinib in non-small cell lung cancer harbouring the BRAF V600E mutation: a case report\",\"authors\":\"H. Oi, K. Yoh, S. Matsumoto, H. Izumi, Y. Shibata, T. Sakai, K. Nosaki, Y. Zenke, K. Goto\",\"doi\":\"10.21037/pcm-21-55\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":74487,\"journal\":{\"name\":\"Precision cancer medicine\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Precision cancer medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.21037/pcm-21-55\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Precision cancer medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21037/pcm-21-55","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}